New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

Updated, longer-term results from the COMMANDS trial show a promising trend toward improved overall survival with ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

The viral immunotherapy delivers a replication-defective herpes simplex virus thymidine kinase gene and was administered in ...

In this week’s edition of InnovationRx, we look at the impact of Trump’s proposed budget cuts on biomedical research and ...

Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...

A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning.

An anti-inflammatory diet may be beneficial for colon cancer survivors, according to a new clinical trial. People who adhered ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

At the heart of innovation is T-win®, a groundbreaking vaccine platform that could change how we treat cancer.